.jpg "H.C. Wainwright Thinks Janux Therapeutics Inc")
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Janux Therapeutics Inc (JANX – Research Report) today and set a price target of $35.00. The company’s shares closed last Thursday at $19.01, close to its 52-week low of $16.32.
According to TipRanks.com, Ramakanth is a 5-star analyst with an average return of 25.3% and a 49.4% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals, Corcept Therapeutics, and Bicycle Therapeutics.
Currently, the analyst consensus on Janux Therapeutics Inc is a Moderate Buy with an average price target of $35.00, an 81.5% upside from current levels. In a report issued on November 10, Evercore ISI also maintained a Buy rating on the stock with a $35.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $37.99 and a one-year low of $16.32. Currently, Janux Therapeutics Inc has an average volume of 138.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer.
Read More on JANX:
- Analysts’ Top Healthcare Picks: EDAP TMS (EDAP), Immunic (IMUX)
- H.C. Wainwright Thinks Calliditas Therapeutics’ Stock is Going to Recover
- H.C. Wainwright Thinks Lantern Pharma’s Stock is Going to Recover
- H.C. Wainwright Thinks Novan’s Stock is Going to Recover
- Analysts Offer Insights on Conglomerates Companies: BioHiTech Global (BHTG) and Hafnia (OtherHFIAF)
